CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Operating activities
Net Income (Loss) Attributable to Parent	$ (86,985)	$ (116,730)
Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]
Credit loss expense	949	1,440
Depreciation and amortization	30,695	20,273
Amortization of financing costs charged to interest expense	1,192	701
Accretion of debt discount and non-cash interest expense	0	7,078
Amortization of right-of-use assets	4,230	3,770
Stock-based compensation expense	32,194	37,415
Goodwill impairment	83,149	0
Change in fair value of contingent consideration	(114,144)	7,741
Other non-cash expense, net	10,524	1,275
Increase (Decrease) in Income Taxes	(1,446)	0
Deferred implementation costs	0	2,343
Change in operating assets and liabilities:
Accounts receivable	15,082	(757)
Prepaid expenses and other assets	(456)	(1,296)
Accounts payable	111	42
Increase (Decrease) in Accrued Liabilities	(5,814)	(2,626)
Partner Share liability	(5,836)	(2,171)
Consumer Incentive liability	(4,248)	3,534
Net cash used in operating activities	(40,803)	(37,968)
Investing activities
Acquisition of property and equipment	(1,090)	(2,145)
Acquisition of patents	(73)	(68)
Capitalized software development costs	(9,170)	(6,937)
Business acquisitions, net of cash acquired	(2,274)	(494,131)
Net cash used in investing activities	(12,607)	(503,281)
Financing activities
Principal payments of debt	(24)	0
Proceeds from issuance of common stock	397	486,163
Payments of Stock Issuance Costs	0	(190)
Payments for Repurchase of Common Stock	40,000	0
Debt issuance costs	(181)	(200)
Net cash received provided by (used in) financing activities	(39,808)	485,773
Payments for Repurchase of Common Stock	40,000	0
Effect of exchange rates on cash, cash equivalents and restricted cash	(1,756)	(393)
Net decrease in cash, cash equivalents and restricted cash	(94,974)	(55,869)
Cash, cash equivalents, and restricted cash — Beginning of period	233,562	293,349
Cash, cash equivalents, and restricted cash — End of period	138,588	237,480
Reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheet:
Cash and cash equivalents	138,514	237,372
Restricted cash	74	108
Total cash, cash equivalents and restricted cash — End of period	138,588	237,480
Supplemental schedule of non-cash investing and financing activities:
Cash paid for interest	2,358	2,308
Common stock purchase consideration for the acquisition of Dosh	0	117,354
Value of shares of common stock	11,937	3,593
Amounts accrued for property and equipment and capitalized software development costs	0	1,016
Deferred Policy Acquisition Costs, Amortization Expense, Excluding Accrued Interest	$ 0	$ 462